Advancement in integrin facilitated drug delivery

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 111-143

  Arosio, Daniela ^a   Casagrande, Cesare ^b  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Drug delivery; ECM proteins; Integrins; Nanoparticles; Peptidomimetics; RGD

Indexed keywords

BIOLOGY; CELLS; DRUG DELIVERY; ENDOTHELIAL CELLS; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOLOGY; NANOPARTICLES; OLIGONUCLEOTIDES; PROTEINS; TISSUE; TUMORS;

CANCER; ECM PROTEINS; INTEGRINS; PEPTIDOMIMETICS; RGD;

DISEASES;

ALBUMIN; ALPHAVBETA6 INTEGRIN; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CHITOSAN; CHITOSAN NANOPARTICLE; CISPLATIN; DISULFIDE; DOXORUBICIN; FERRITIN; FLUOROURACIL; FUMAGILLIN; GRAPHENE; GRAPHENE OXIDE; INTEGRIN; IRINOTECAN; NANOPARTICLE; PACLITAXEL; PLATINUM COMPLEX; PRODRUG; PROTEINASE; SCLEROPROTEIN; SILICA NANOPARTICLE; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE;

ACIDITY; ANGIOGENESIS; BRAIN TUMOR; CANCER CELL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER TISSUE; CELL ORGANELLE; CIRCULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE TARGETING; GENE THERAPY; HUMAN; INTERNALIZATION; KIDNEY CARCINOMA; METASTASIS; MICROBUBBLE; NANOMEDICINE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; STROMA; ANIMAL; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; INTEGRINS; NANOPARTICLES; NEOPLASMS; PRODRUGS;

EID: 84957798818     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.12.001     Document Type: Review

References (285)

1. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 2008, 8:604-617. 10.1038/nrc2353.
2. Alghisi G.C., Rüegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006, 13:113-135.
3. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22. 10.1038/nrc2748.
4. Cox D., Brennan M., Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 2010, 9:804-820. 10.1038/nrd3266.
5. Millard M., Odde S., Neamati N. Integrin targeted therapeutics. Theranostics 2011, 1:154-188.
6. Goodman S.L., Picard M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 2012, 33:405-412. 10.1016/j.tips.2012.04.002.
7. Marelli U.K., Rechenmacher F., Sobahi T.R., Mas-Moruno C., Kessler H. Tumor targeting via integrin ligands. Front. Oncol. 2013, 3:222. 10.3389/fonc.2013.00222.
8. Reynolds A.R., Hart I.R., Watson A.R., Welti J.C., Silva R.G., Robinson S.D., Da Violante G., Gourlaouen M., Salih M., Jones M.C., Jones D.T., Saunders G., Kostourou V., Perron-Sierra F., Norman J.C., Tucker G.C., Hodivala-Dilke K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 2009, 15:392-400. 10.1038/nm.1941.
9. Panzeri S., Zanella S., Arosio D., Vahdati L., Dal Corso A., Pignataro L., Paolillo M., Schinelli S., Belvisi L., Gennari C., Piarulli U. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists. Chem. Eur. J. 2015, 21:6265-6271. 10.1002/chem.201406567.
10. Venning F.A., Wullkopf L., Erler J.T. Targeting ECM disrupts cancer progression. Front. Oncol. 2015, 5:224. 10.3389/fonc.2015.00224. eCollection 2015.
11. Miles F.L., Sikes R.A. Insidious changes in stromal matrix fuel cancer progression. Mol. Cancer Res. 2014, 12:297-312. 10.1158/1541-7786.MCR-13-0535.
12. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res. 2010, 339:269-280. 10.1007/s00441-009-0834-6.
13. Bandyopadhyay A., Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets 2009, 10:645-652.
14. Arosio D., Casagrande C., Manzoni L. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles. Curr. Med. Chem. 2012, 19:3128-3151.
15. Chen K., Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics 2011, 1:189-200.
16. Wang Z., Chui W.K., Ho P.C. Integrin targeted drug and gene delivery. Expert Opin. Drug Deliv. 2010, 7:159-171. 10.1517/17425240903468696.
17. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
18. Dupuy A.G., Caron E. Integrin-dependent phagocytosis: spreading from microadhesion to new concepts. J. Cell Sci. 2008, 121:1773-1783. 10.1242/jcs.018036.
19. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 2008, 26:552-558. 10.1016/j.tibtech.2008.06.007.
20. Nasongkla N., Bey E., Ren J., Ai H., Khemtong C., Guthi J.S., Chin S.F., Sherry A.D., Boothman D.A., Gao J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006, 6:2427-2430.
21. Khemtong C., Kessinger C.W., Ren J., Bey E.A., Yang S.G., Guthi J.S., Boothman D.A., Sherry A.D., Gao J. In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res. 2009, 69:1651-1658. 10.1158/0008-5472.CAN-08-3231.
22. Xiong X.B., Mahmud A., Uludağ H., Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm. Res. 2008, 25:2555-2566. 10.1007/s11095-008-9673-5.
23. Zhao H., Wang J.C., Sun Q.S., Luo C.L., Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug Target. 2009, 17:10-18. 10.1080/10611860802368966.
24. Jiang X., Xin H., Gu J., Xu X., Xia W., Chen S., Xie Y., Chen L., Chen Y., Sha X., Fang X. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 2013, 34:1739-1746. 10.1016/j.biomaterials.2012.11.016.
25. Jiang X., Sha X., Xin H., Xu X., Gu J., Xia W., Chen S., Xie Y., Chen L., Chen Y., Fang X. Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials 2013, 34:2969-2979. 10.1016/j.biomaterials.2012.12.049.
26. Kiessling F., Huppert J., Zhang C., Jayapaul J., Zwick S., Woenne E.C., Mueller M.M., Zentgraf H., Eisenhut M., Addadi Y., Neeman M., Semmler W. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 2009, 253:462-469. 10.1148/radiol.2532081815.
27. Zhang C., Jugold M., Woenne E.C., Lammers T., Morgenstern B., Mueller M.M., Zentgraf H., Bock M., Eisenhut M., Semmler W., Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007, 67:1555-1562.
28. Gray B.P., McGuire M.J., Brown K.C. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One 2013, 8:e72938. (2013). 10.1371/journal.pone.0072938.eCollection.
29. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
30. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98:335-344.
31. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910. 10.1126/science.1226338.
32. Haubner R., Finsinger D., Kessler H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(V)beta(3) integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl. 1997, 36:1375-1389.
33. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., Goodmann S.L., Kessler H. N-methilated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonist. J. Med. Chem. 1999, 42:3033-3040.
34. Auzzas L., Zanardi F., Battistini L., Burreddu P., Carta P., Rassu G., Curti C., Casiraghi G. Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Curr. Med. Chem. 2010, 17:1255-1299.
35. Paolillo M., Russo M.A., Serra M., Colombo L., Schinelli S. Small molecule integrin antagonists in cancer therapy. Mini Rev. Med. Chem. 2009, 9:1439-1446.
36. Xiong X.B., Ma Z.S., Lai R., Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010, 31:757-768. (Erratum in: Biomaterials 32 (2011) 4194. Dosage error in article text). 10.1016/j.biomaterials.2009.09.080.
37. Xiong X.B., Uludağ H., Lavasanifar A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials 2010, 31:5886-5893. 10.1016/j.biomaterials.2010.03.075.
38. Xiong X.B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 28:5202-5213. 10.1021/nn2013707.
39. de Groot F.M., Broxterman H.J., Adams H.P., van Vliet A., Tesser G.I., Elderkamp Y.W., Schraa A.J., Kok R.J., Molema G., Pinedo H.M., Scheeren H.W. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol. Cancer Ther. 2002, 1:901-911.
40. Wang H., Chen K., Cai W., Li Z., He L., Kashefi A., Chen X. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol. Cancer Ther. 2008, 7:1044-1053. 10.1158/1535-7163.MCT-07-2084.
41. Zhen Z., Tang W., Guo C., Chen H., Lin X., Liu G., Fei B., Chen X., Xu B., Xie J. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer. ACS Nano 2013, 7:6988-6996. 10.1021/nn402199g.
42. Zhen Z., Tang W., Chen H., Lin X., Todd T., Wang G., Cowger T., Chen X., Xie J. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 2013, 7:4830-4837. 10.1021/nn305791q.
43. Manzoni L., Belvisi L., Arosio D., Civera M., Pilkington-Miksa M., Potenza D., Caprini A., Araldi E.M., Monferini E., Mancino M., Podestà F., Scolastico C. Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting. ChemMedChem 2009, 4:615-632. 10.1002/cmdc.200800422.
44. Arosio D., Manzoni L., Araldi E.M., Caprini A., Monferini E., Scolastico C. Functionalized cyclic RGD peptidomimetics: conjugable ligands for αvβ3 receptor imaging. Bioconjug. Chem. 2009, 20:1611-1617. 10.1021/bc900155j.
45. 3 integrin in glioblastoma xenografts. Contrast Media Mol. Imaging 2011, 6:449-458. 10.1002/cmmi.444.
46. Manzoni L., Belvisi L., Arosio D., Bartolomeo M.P., Bianchi A., Brioschi C., Buonsanti F., Cabella C., Casagrande C., Civera M., De Matteo M., Fugazza L., Lattuada L., Maisano F., Miragoli L., Neira C., Pilkington-Miksa M., Scolastico C. Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes. ChemMedChem 2012, 7:1084-1093. 10.1002/cmdc.201200043.
47. 68Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur. J. Nucl. Med. Mol. Imaging 2013, 40:1265-1274. 10.1007/s00259-013-2432-9.
48. Pilkington-Miksa M., Arosio D., Battistini L., Belvisi L., De Matteo M., Vasile F., Burreddu P., Carta P., Rassu G., Perego P., Carenini N., Zunino F., De Cesare M., Castiglioni V., Scanziani E., Scolastico C., Casiraghi G., Zanardi F., Manzoni L. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Bioconjug. Chem. 2012, 23:1610-1622. 10.1021/bc300164t.
49. Bianchi A., Arosio D., Perego P., De Cesare M., Carenini N., Zaffaroni N., De Matteo M., Manzoni L. Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Org. Biomol. Chem. 2015, 13:7530-7541. 10.1039/c5ob00497g.
50. Battistini L., Burreddu P., Sartori A., Arosio D., Manzoni L., Paduano L., D'Errico G., Sala R., Reia L., Bonomini S., Rassu G., Zanardi F. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes. Mol. Pharm. 2014, 11:2280-2293. 10.1021/mp400718j.
51. Colombo R., Mingozzi M., Belvisi L., Arosio D., Piarulli U., Carenini N., Perego P., Zaffaroni N., De Cesare M., Castiglioni V., Scanziani E., Gennari C. Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. J. Med. Chem. 2012, 55:10460-10474. 10.1021/jm301058f.
52. Dal Corso A., Caruso M., Belvisi L., Arosio D., Piarulli U., Albanese C., Gasparri F., Marsiglio A., Sola F., Troiani S., Valsasina B., Pignataro L., Donati D., Gennari C. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers. Chem. Eur. J. 2015, 21:6921-6929. 10.1002/chem.201500158.
53. Spitaleri A., Mari S., Curnis F., Traversari C., Longhi R., Bordignon C., Corti A., Rizzardi G.P., Musco G. Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. J. Biol. Chem. 2008, 283:19757-19768. 10.1074/jbc.M710273200.
54. Hou L., Zhao X., Wang P., Ning Q., Meng M., Liu C. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells. PLoS One 2013, 8. 10.1371/journal.pone.0053491.
55. Curnis F., Sacchi A., Longhi R., Colombo B., Gasparri A., Corti A. IsoDGR-tagged albumin: a new αvβ3 selective carrier for nanodrug delivery to tumors. Small 2013, 9:673-678.
56. Pisano M., Paola I.D.E., Nieddu V., Sassu I., Cossu S., Galleri G., Del Gatto A., Budroni M., Cossu A., Saviano M., Palmieri G., Zaccaro L., Rozzo C. In vitro activity of the αvβ3 integrin antagonist RGDechi-hCit on malignant melanoma cells. Anticancer Res. 2013, 33:871-879.
57. Capasso D., de Paola I., Liguoro A., Del Gatto A., Di Gaetano S., Guarnieri D., Saviano M., Zaccaro L. RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells. PLoS One 2014, 9. 10.1371/journal.pone.0106441. eCollection 2014.
58. Del Gatto A., Zaccaro L., Grieco P., Novellino E., Zannetti A., Del Vecchio S., Iommelli F., Salvatore M., Pedone C., Saviano M. Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behaviour. J. Med. Chem. 2006, 49:3416-3420.
59. Zhang H., Aina O.H., Lam K.S., de Vere White R., Evans C., Henderson P., Lara P.N., Wang X., Bassuk J.A., Pan C.X. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. 2012, 30:635-645. 10.1016/j.urolonc.2010.06.011.
60. Lin T.Y., Zhang H., Luo J., Li Y., Gao T., Lara P.N., de Vere White R., Lam K.S., Pan C.X. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomedicine 2012, 7:2793-2804. 10.2147/IJN.S27734.
61. Lin T.Y., Li Y.P., Zhang H., Luo J., Goodwin N., Gao T., de Vere White R., Lam K.S., Pan C.X. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (London) 2013, 8:1239-1251. 10.2217/nnm.12.150.
62. 6-specific ligand for in vitro and in vivo applications. Mol. Cancer Ther. 2009, 8:1239-1249. 10.1158/1535-7163.MCT-08-1098.
63. 6-positive cancers. Bioconjug. Chem. 2008, 19:1813-1821. 10.1021/bc800154f.
64. 6. Bioorg. Med. Chem. 2011, 19:5480-5489. 10.1016/j.bmc.2011.07.046.
65. Guthi J.S., Yang S.-G., Huang G., Li S., Khemtong C., Kessinger C.W., Peyton M., Minna J.D., Brown K.C., Gao J. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm. 2010, 7:32-40. 10.1021/mp9001393.
66. Gray B.P., Li S., Brown K.C. From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug. Chem. 2013, 24:85-96. 10.1021/bc300498d.
67. Rechenmacher F., Neubauer S., Polleux J., Mas-Moruno C., De Simone M., Cavalcanti-Adam E.A., Spatz J.P., Fässler R., Kessler H. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro. Angew. Chem. Int. Ed. 2013, 52:1572-1575. 10.1002/anie.201206370.
68. Neubauer S., Rechenmacher F., Beer A.J., Curnis F., Pohle K., D'Alessandria C., Wester H.J., Reuning U., Corti A., Schwaiger M., Kessler H. Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. Angew. Chem. Int. Ed. Engl. 2013, 52:11656-11659. 10.1002/anie.201306376.
69. Neubauer S., Rechenmacher F., Brimioulle R., Di Leva F.S., Bochen A., Sobahi T.R., Schottelius M., Novellino E., Mas-Moruno C., Marinelli L., Kessler H. Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity. J. Med. Chem. 2014, 57:3410-3417. 10.1021/jm500092w.
70. Dai W., Yang T., Wang X., Wang J., Zhang X., Zhang Q. PHSCNK-modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J. Drug Target. 2010, 18:254-263. 10.3109/10611860903353354.
71. Mardilovich A., Craig J.A., McCammon M.Q., Garg A., Kokkoli E. Design of a novel fibronectin-mimetic peptide-amphiphile for functionalized biomaterials. Langmuir 2006, 22:3259-3264.
72. Garg A., Tisdale A.W., Haidari E., Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 2009, 366:201-210. 10.1016/j.ijpharm.2008.09.016.
73. Shroff K., Kokkoli E. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDAMB-231 breast cancer cells. Langmuir 2012, 28:4729-4736. 10.1021/la204466g.
74. Petersen M.A., Hillmyer M.A., Kokkoli E. Bioresorbable polymersomes for targeted delivery of cisplatin. Bioconjug. Chem. 2013, 24:533-543. 10.1021/bc3003259.
75. Pangburn T.O., Georgiou K., Bates F.S., Kokkoli E. Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir 2012, 28:12816-12830. 10.1021/la300874z.
76. Adil M.M., Erdman Z.S., Kokkoli E. Transfection mechanisms of polyplexes, lipoplexes, and stealth liposomes in α5β1 integrin bearing DLD-1 colorectal cancer cells. Langmuir 2014, 30:3802-3810. 10.1021/la5001396.
77. Adil M.M., Levine R.M., Kokkoli E. Increasing cancer-specific gene expression by targeting overexpressed α5β1 integrin and upregulated transcriptional activity of NF-κB. Mol. Pharm. 2014, 11:849-858. 10.1021/mp400535v.
78. Wang D., Fei B., Halig L.V., Qin X., Hu Z., Xu H., Wang Y.A., Chen Z., Kim S., Shin D.M., Chen Z.G. Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano 2014, 8:6620-6632.
79. Kiziltepe T., Ashley J.D., Stefanick J.F., Qi Y.M., Alves N.J., Handlogten M.W., Suckow M.A., Navari R.M., Bilgicer B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012, 2. 10.1038/bcj.2012.10.
80. Stefanick J.F., Ashley J.D., Kiziltepe T., Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 2013, 23:2935-2947. 10.1021/nn305663e.
81. Stefanick J.F., Ashley J.D., Bilgicer B. Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. ACS Nano 2013, 24:8115-8127. 10.1021/nn4033954.
82. Staatz W.D., Fok K.F., Zutter M.M., Adams S.P., Rodriguez B.A., Santoro S.A. Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J. Biol. Chem. 1991, 266:7363-7367.
83. Huang C.W., Li Z., Conti P.S. In vivo near-infrared fluorescence imaging of integrin α2β1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe. J. Nucl. Med. 2011, 52:1979-1986. 10.2967/jnumed.111.091256.
84. Huang C.W., Li Z., Cai H., Chen K., Shahinian T., Conti P.S. Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:1313-1322. 10.1007/s00259-011-1752-x.
85. Salaam A.D., Hwang P., McIntosh R., Green H.N., Jun H.W., Dean D. Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer. Beilstein J. Nanotechnol. 2014, 5(2014):937-945. 10.3762/bjnano.5.107.eCollection.
86. Chung Y.H., Hsu P.H., Huang C.W., Hsieh W.C., Huang F.T., Chang W.C., Chiu H., Hsu S.T., Yen T.C. Evaluation of prognostic integrin α2β1 PET tracer and concurrent targeting delivery using focused ultrasound for brain glioma detection. Mol. Pharm. 2014, 11:3904-3914. 10.1021/mp500296n.
87. Miller M.W., Basra S., Kulp D.W., Billings P.C., Choi S., Beavers M.P., McCarty O.J., Zou Z., Kahn M.L., Bennett J.S., DeGrado W.F. Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:719-724. 10.1073/pnas.0811622106.
88. Ivaska J., Käpylä J., Pentikäinen O., Hoffrén A.M., Hermonen J., Huttunen P., Johnson M.S., Heino J. A peptide inhibiting the collagen binding function of integrin alpha2I domain. J. Biol. Chem. 1999, 274:3513-3521. (Ivaska 1999).
89. 1 receptor. Int. J. Pharm. 2012, 428:171-177. 10.1016/j.ijpharm.2012.02.043.
90. Wong P.T., Choi S.K. Mechanisms of drug release in nanotherapeutic delivery systems. Chem. Rev. 2015, 115:3388-3432. 10.1021/cr5004634.
91. Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., Liang X.J. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 2014, 32:693-710. 10.1016/j.biotechadv.2013.11.009.
92. 3 integrin-targeted peptide/peptidomimetic-drug conjugates: in-depth analysis of the linker technology. Curr. Top. Med. Chem. 2015, 10.2174/1568026615666150701114343.
93. Wang K., Zhang X., Liu Y., Liu C., Jiang B., Jiang Y. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 2014, 35:8735-8747. 10.1016/j.biomaterials.2014.06.042.
94. Zhang L., Zhu S., Qian L., Pei Y., Qiu Y., Jiang Y. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharm. Biopharm. 2011, 79:232-240. 10.1016/j.ejpb.2011.03.025.
95. 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011, 32:4151-4160. 10.1016/j.biomaterials.2011.02.006.
96. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., Zhang Y., Barnhart T.E., Cai W., Gong S. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33:3071-3082. 10.1016/j.biomaterials.2011.12.030.
97. Peng Z.H., Kopeček J. Enhancing accumulation and penetration of HPMA copolymer-doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 cleavable spacer. J. Am. Chem. Soc. 2015, 137:6726-6729. 10.1021/jacs.5b00922.
98. Kingston D.G. Recent advances in the chemistry of taxol. J. Nat. Prod. 2000, 63:726-734.
99. Chen X., Plasencia C., Hou Y., Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem. 2005, 48:1098-1106. (Erratum in J. Med. Chem. 48 (2005) 5874).
100. Cao Q., Li Z.B., Chen K., Wu Z., He L., Neamati N., Chen X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:1489-1498. 10.1007/s00259-008-0744-y.
101. Ryppa C., Mann-Steinberg H., Biniossek M.L., Satchi-Fainaro R., Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin αVβ3. Int. J. Pharm. 2009, 368:89-97. 10.1016/j.ijpharm.2008.09.055.
102. Choi K.Y., Swierczewska M., Lee S., Chen X. Protease-activated drug development. Theranostics 2012, 2:156-178. 10.7150/thno.4068.
103. 2] that targets integrin αvβ3. Bioconjug. Chem. 2008, 19:1414-1422. 10.1021/bc800117r.
104. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., Hanahan D., Mattrey R.F., Ruoslahti E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520. 10.1016/j.ccr.2009.10.013.
105. Dal Pozzo A., Ni M.H., Esposito E., Dallavalle S., Musso L., Bargiotti A., Pisano C., Vesci L., Bucci F., Castorina M., Foderà R., Giannini G., Aulicino C., Penco S. Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. Bioorg. Med. Chem. 2010, 18:64-72. 10.1016/j.bmc.2009.11.019.
106. Dal Pozzo A., Esposito E., Ni M., Muzi L., Pisano C., Bucci F., Vesci L., Castorina M., Penco S. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β3 integrin ligands: an approach to tumor-targeted therapy. Bioconjug. Chem. 2010, 21:1956-1967. 10.1021/bc100097r.
107. Wu M.H., Yan B., Humerickhouse R., Dolan M.E. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin. Cancer Res. 2002, 8:2696-2700.
108. Iwama S., Kitano T., Fukuya F., Honda Y., Sato Y., Notako M., Morie T. Discovery of a potent and selective alpha v beta 3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model. Bioorg. Med. Chem. Lett. 2004, 14:2567-2570.
109. Alloatti D., Giannini G., Vesci L., Castorina M., Pisano C., Badaloni E., Cabri W. Camptothecins in tumor homing via an RGD sequence mimetic. Bioorg. Med. Chem. Lett. 2012, 22:6509-6512. 10.1016/j.bmcl.2012.07.061.
110. Lee M.H., Kim J.Y., Han J.H., Bhuniya S., Sessler J.L., Kang C., Kim J.S. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug. J. Am. Chem. Soc. 2012, 134:12668-12674. 10.1021/ja303998y.
111. Graf N., Lippard S.J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Deliv. Rev. 2012, 64:993-1004. 10.1016/j.addr.2012.01.007.
112. Mukhopadhyay S., Barnés C.M., Haskel A., Short S.M., Barnes K.R., Lippard S.J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug. Chem. 2008, 19:39-49.
113. Graf N., Bielenberg D.R., Kolishetti N., Muus C., Banyard J., Farokhzad O.C., Lippard S.J. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 2012, 6:4530-4539. 10.1021/nn301148e.
114. Rieter W.J., Pott K.M., Taylor K.M.L., Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc. 2008, 130:11584-11585.
115. Taylor-Pashow K.M.L., Della Rocca J., Xie Z., Tran S., Lin W. Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery. J. Am. Chem. Soc. 2009, 131:14261-14263.
116. Yuan Y., Kwok R.T., Tang B.Z., Liu B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J. Am. Chem. Soc. 2014, 136:2546-2554. 10.1021/ja411811w.
117. Yuan Y., Kwok R.T., Zhang R., Tang B.Z., Liu B. Targeted theranostic prodrugs based on an aggregation-induced emission (AIE) luminogen for real-time dual-drug tracking. Chem. Commun. 2014, 50:11465-11468. 10.1039/c4cc05255b.
118. Massaguer A., González-Cantó A., Escribano E., Barrabés S., Artigas G., Moreno V., Marchán V. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Dalton Trans. 2015, 44:202-212. 10.1039/c4dt02710h.
119. Boturyn D., Defrancq E., Dolphin G.T., Garcia J., Labbe P., Renaudet O., Dumy P. RAFTNano-constructs: surfing to biological applications. J. Pept. Sci. 2008, 14:224-240.
120. Sancey L., Garanger E., Foillard S., Schoehn G., Hurbin A., Albiges-Rizo C., Boturyn D., Souchier C., Grichine A., Dumy P., Coll J.L. Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide. Mol. Ther. 2009, 17:837-843. 10.1038/mt.2009.29.
121. Sancey L., Ardisson V., Riou L.M., Ahmadi M., Marti-Batlle D., Boturyn D., Dumy P., Fagret D., Ghezzi C., Vuillez J.P. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:2037-2047.
122. Galibert M., Jin Z.H., Furukawa T., Fukumura T., Saga T., Fujibayashi Y., Dumy P., Boturyn D. RGD-cyclam conjugate: synthesis and potential application for positron emission tomography. Bioorg. Med. Chem. Lett. 2010, 20:5422-5425. 10.1016/j.bmcl.2010.07.114.
123. Dufort S., Sancey L., Hurbin A., Foillard S., Boturyn D., Dumy P., Coll J.L. Targeted delivery of a proapoptotic peptide to tumors in vivo. J. Drug Target. 2011, 19:582-588. 10.3109/1061186X.2010.542245.
124. Foillard S., Sancey L., Coll J.L., Boturyn D., Dumy P. Targeted delivery of activatable fluorescent pro-apoptotic peptide into live cells. Org. Biomol. Chem. 2009, 21:221-224. 10.1039/b817251j.
125. Winter P.M., Neubauer A.M., Caruthers S.D., Harris T.D., Robertson J.D., Williams T.A., Schmieder A.H., Hu G., Allen J.S., Lacy E.K., Zhang H., Wickline S.A., Lanza G.M. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2103-2109.
126. Schmieder A.H., Caruthers S.D., Zhang H., Williams T.A., Robertson J.D., Wickline S.A., Lanza G.M. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDAMB-435 xenograft mouse model. FASEB J. 2008, 22:4179-4189. 10.1096/fj.08-112060.
127. Winter P.M., Caruthers S.D., Zhang H., Williams T.A., Wickline S.A., Lanza G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging 2008, 1:624-634. 10.1016/j.jcmg.2008.06.003.
128. Winter P.M., Schmieder A.H., Caruthers S.D., Keene J.L., Zhang H., Wickline S.A., Lanza G.M. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008, 22:2758-2767. 10.1096/fj.07-103929.
129. Zhou H.F., Chan H.W., Wickline S.A., Lanza G.M., Pham C.T. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009, 23:2978-2985. 10.1096/fj.09-129874.
130. Zhou H.F., Hu G., Wickline S.A., Lanza G.M., Pham C.T. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (London) 2010, 5:1065-1074. 10.2217/nnm.10.78.
131. Pan D., Sanyal N., Schmieder A.H., Senpan A., Kim B., Yang X., Hu G., Allen J.S., Gross R.W., Wickline S.A., Lanza G.M. Anti-angiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (London) 2012, 7:1507-1519. 10.2217/nnm.12.27.
132. Zhou H.F., Yan H., Senpan A., Wickline S.A., Pan D., Lanza G.M., Pham C.T.N. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials 2012, 33:8632-8640. 10.1016/j.biomaterials.
133. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760. 10.1038/nnano.2007.387.
134. van der Meel R., Vehmeijer L.J., Kok R.J., Storm G., van Gaal E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 2013, 65:1284-1298. 10.1016/j.addr.2013.08.012.
135. Harries M., Ellis P., Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 2005, 23:7768-7771.
136. ®-the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134. 10.1016/j.jconrel.2012.03.020.
137. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., Welles L., Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36. TLC D-99 Study Group.
138. Edwards R.S., Coleman K.S. Graphene synthesis: relationship to applications. Nanoscale 2013, 5:38-51. 10.1039/c2nr32629a.
139. Yang K., Feng L., Shi X., Liu Z. Nano-graphene in biomedicine: theranostic applications. Chem. Soc. Rev. 2013, 42:530-547. 10.1039/c2cs35342c.
140. Liu J., Cui L., Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 2013, 9:9243-9257. 10.1016/j.actbio.2013.08.016.
141. Robinson J.T., Tabakman S.M., Liang Y., Wang H., Casalongue H.S., Vinh D., Dai H. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J. Am. Chem. Soc. 2011, 133:6825-6831. 10.1021/ja2010175.
142. Wang C., Chen B., Zou M., Cheng G. Cyclic RGD-modified chitosan/graphene oxide polymers for drug delivery and cellular imaging. Colloids Surf. B: Biointerfaces 2014, 122:332-340. 10.1016/j.colsurfb.2014.07.018.
143. Zhou T., Zhou X., Xing D. Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarriers. Biomaterials 2014, 35:4185-4194. 10.1016/j.biomaterials.2014.01.044.
144. Chen D., Dougherty C.A., Zhu K., Hong H. Theranostic applications of carbon nanomaterials in cancer: focus on imaging and cargo delivery. J. Control. Release 2015, 210:230-245. 10.1016/j.jconrel.2015.04.021.
145. Wu S.H., Mou C.Y., Lin H.P. Synthesis of mesoporous silica nanoparticles. Chem. Soc. Rev. 2013, 42:3862-3875. 10.1039/c3cs35405a.
146. Wang Y., Zhao Q., Han N., Bai L., Li J., Liu J., Che E., Hu L., Zhang Q., Jiang T., Wang S. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine 2015, 11:313-327. 10.1016/j.nano.2014.09.014.
147. Mamaeva V., Sahlgren C., Lindén M. Mesoporous silica nanoparticles in medicin-recent advances. Adv. Drug Deliv. Rev. 2013, 65:689-702. 10.1016/j.addr.2012.07.018.
148. Yang P., Gai S., Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem. Soc. Rev. 2012, 41:3679-3698. 10.1039/c2cs15308d.
149. Ferris D.P., Lu J., Gothard C., Yanes R., Thomas C.R., Olsen J.C., Stoddart J.F., Tamanoi F., Zink J.I. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small 2011, 7:1816-1826. 10.1002/smll.201002300.
150. Pan L., Liu J., He Q., Shi J. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression. Adv. Mater. 2014, 26:6742-6748. 10.1002/adma.201402752.
151. Zhang J., Yuan Z.F., Wang Y., Chen W.-H., Luo G.F., Cheng S.X., Zhuo R.-X., Zhang X.Z. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. J. Am. Chem. Soc. 2013, 135:5068-5073. 10.1021/ja312004m.
152. Chen H., Zhen Z., Tang W., Todd T., Chuang Y.J., Wang L., Pan Z., Xie J. Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics 2013, 3:650-657. (eCollection 2013). 10.7150/thno.6668.
153. Zhu Y., Sundaram H.S., Liu S., Zhang L., Xu X., Yu Q., Xu J., Jiang S. A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles. Biomacromolecules 2014, 15:1845-1851. 10.1021/bm500209a.
154. Liao Y.T., Wu K.C.W., Yu J. Synthesis of mesoporous silica nanoparticle-encapsulated alginate microparticles for sustained release and targeting therapy. J. Biomed. Mater. Res. B Appl. Biomater. 2014, 102:293-302. 10.1002/jbm.b.33007.
155. Liao Y.T., Liu C.H., Yu J., Wu K.C.W. Liver cancer cells: targeting and prolonged-release drug carriers consisting of mesoporous silica nanoparticles and alginate microspheres. Int. J. Nanomedicine 2014, 5:2767-2778. 10.2147/IJN.S60171. eCollection 2014.
156. Wang C.F., Mäkilä E.M., Kaasalainen M.H., Liu D., Sarparanta M.P., Airaksinen A.J., Salonen J.J., Hirvonen J.T., Santos H.A. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. Biomaterials 2014, 35:1257-1266. 10.1016/j.biomaterials.2013.10.065.
157. Hansson A., Di Francesco T., Falson F., Rousselle P., Jordan O., Borchard G. Preparation and evaluation of nanoparticles for directed tissue engineering. Int. J. Pharm. 2012, 439:73-80. 10.1016/j.ijpharm.2012.09.053.
158. Chua P.H., Neoh K.G., Kang E.T., Wang W. Surface functionalization of titanium with hyaluronic acid/chitosan polyelectrolyte multilayers and RGD for promoting osteoblast functions and inhibiting bacterial adhesion. Biomaterials 2008, 29:1412-1421. 10.1016/j.biomaterials.2007.12.019.
159. Lee J.Y., Choo J.E., Choi Y.S., Shim I.K., Lee S.J., Seol Y.J., Chung C.P., Park Y.J. Effect of immobilized cell-binding peptides on chitosan membranes for osteoblastic differentiation of mesenchymal stem cells. Biotechnol. Appl. Biochem. 2009, 52:69-77. 10.1042/BA20070169.
160. Mochizuki M., Yamagata N., Philp D., Hozumi K., Watanabe T., Kikkawa Y., Kadoya Y., Kleinman H.K., Nomizu M. Integrin-dependent cell behavior on ECM peptide-conjugated chitosan membranes. Biopolymers 2007, 88:122-130.
161. Kim J.H., Kim Y.S., Park K., Kang E., Lee S., Nam H.Y., Kim K., Park J.H., Chi D.Y., Park R.W., Kim I.S., Choi K., Chan Kwon I. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 2008, 29:1920-1930. 10.1016/j.biomaterials.2007.12.038.
162. Cai L.L., Liu P., Li X., Huang X., Ye Y.Q., Chen F.Y., Yuan H., Hu F.Q., Du Y.Z. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int. J. Nanomedicine 2011, 6:3499-3508. 10.2147/IJN.S26670.
163. Hu F.Q., Meng P., Dai Y.Q., Du Y.Z., You J., Wei X.H., Yuan H. PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy. Eur. J. Pharm. Biopharm. 2008, 70:749-757. 10.1016/j.ejpb.2008.06.015.
164. Lv P.P., Ma Y.F., Yu R., Yue H., Ni D.Z., Wei W., Ma G.H. Targeted delivery of insoluble cargo (paclitaxel) by PEGylated chitosan nanoparticles grafted with Arg-Gly-Asp (RGD). Mol. Pharm. 2012, 4:1736-1747. 10.1021/mp300051h.
165. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., Nam E.J., Mora E.M., Stone R.L., Lu C., Lee S.J., Roh J.W., Nick A.M., Lopez-Berestein G., Sood A.K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 2010, 16:3910-3922. 10.1158/1078-0432.CCR-10-0005.
166. Alvarez-Lorenzo C., Concheiro A. Bioinspired drug delivery systems. Curr. Opin. Biotechnol. 2013, 24:1167-1173. 10.1016/j.copbio.2013.02.013.
167. Zhen Z., Tang W., Todd T., Xie J. Ferritins as nanoplatforms for imaging and drug delivery. Expert Opin. Drug Deliv. 2014, 11:1913-1922. 10.1517/17425247.2014.941354.
168. Uchida M., Flenniken M.L., Allen M., Willits D.A., Crowley B.E., Brumfield S., Willis A.F., Jackiw L., Jutila M., Young M.J., Douglas T. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 2006, 128:16626-16633.
169. Lin X., Xie J., Niu G., Zhang F., Gao H., Yang M., Quan Q., Aronova M.A., Zhang G., Lee S., Leapman R., Chen X. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett. 2011, 11:814-819. 10.1021/nl104141g.
170. Arslan E., Garip I.C., Gulseren G., Tekinay A.B., Guler M.O. Bioactive supramolecular peptide nanofibers for regenerative medicine. Adv. Healthc. Mater. 2014, 3:1357-1376. 10.1002/adhm.201300491.
171. Soukasene S., Toft D.J., Moyer T.J., Lu H., Lee H.K., Standley S.M., Cryns V.L., Stupp S.I. Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. ACS Nano 2011, 5:9113-9121. 10.1021/nn203343z.
172. Zhang P., Cheetham A.G., Lin Y.A., Cui H. Self-assembled Tat nanofibers as effective drug carrier and transporter. ACS Nano 2013, 7:5965-5977. 10.1021/nn401667z.
173. Liu J., Liu J., Xu H., Zhang Y., Chu L., Liu Q., Song N., Yang C. Novel tumor-targeting, self-assembling peptide nanofiber as a carrier for effective curcumin delivery. Int. J. Nanomedicine 2014, 9:197-207. 10.2147/IJN.S55875.
174. Browning M.B., Guiza V., Russell B., Rivera J., Cereceres S., Höök M., Hahn M.S., Cosgriff-Hernandez E.M. Endothelial cell response to chemical, biological, and physical cues in bioactive hydrogels. Tissue Eng. A 2014, 20:3130-3141. 10.1089/ten.TEA.2013.0602.
175. Browning M.B., Russell B., Rivera J., Höök M., Cosgriff-Hernandez E.M. Bioactive hydrogels with enhanced initial and sustained cell interactions. Biomacromolecules 2013, 14:2225-2233. 10.1021/bm400634j.
176. Hamaia S., Farndale R.W. Integrin recognition motifs in the human collagens. Adv. Exp. Med. Biol. 2014, 819:127-142. 10.1007/978-94-017-9153-3_9.
177. Caracciolo G., Cardarelli F., Pozzi D., Salomone F., Maccari G., Bardi G., Capriotti A.L., Cavaliere C., Papi M., Laganà A. Selective targeting capability acquired with a protein corona adsorbed on the surface of 1,2-dioleoyl-3-trimethylammonium propane/DNA nanoparticles. ACS Appl. Mater. Interfaces 2013, 26:13171-13179. 10.1021/am404171h.
178. Caracciolo G. The protein corona effect for targeted drug delivery. Bioinspired Biomimetic Nanobiomater. 2012, 2:54-57.
179. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132:171-183. 10.1016/j.jconrel.2008.05.010.
180. Kratz F., Elsadek B. Clinical impact of serum proteins on drug delivery. J. Control. Release 2012, 161:429-445. 10.1016/j.jconrel.2011.11.028.
181. Elsadek B., Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release 2012, 157:4-28. 10.1016/j.jconrel.2011.09.069.
182. Ming X., Carver K., Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 2013, 34:7939-7949. 10.1016/j.biomaterials.2013.06.066.
183. Pang H.B., Braun G.B., She Z.G., Kotamraju V.R., Sugahara K.N., Teesalu T., Ruoslahti E. A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. J. Control. Release 2014, 175:48-53. 10.1016/j.jconrel.2013.12.006.
184. Su S., Wang H., Liu X., Wu Y., Nie G. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. Biomaterials 2013, 34:3523-3533. 10.1016/j.biomaterials.2013.01.083.
185. Chen Q., Wang X., Wang C., Feng L., Li Y., Liu Z. Drug-induced self-assembly of modified albumins as nano-theranostics for tumor-targeted combination therapy. ACS Nano 2015, 9:5223-5233. 10.1021/acsnano.5b00640.
186. Tian Y., Li S., Song J., Ji T., Zhu M., Anderson G.J., Wei J., Nie G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35:2383-2390. 10.1016/j.biomaterials.2013.11.083.
187. Fu X., Rivera A., Tao L., Zhang X. Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int. J. Cancer 2013, 133:2483-2492. 10.1002/ijc.28269.
188. Dasa S.S., Jin Q., Chen C.T., Chen L. Target-specific copper hybrid T7 phage particles. Langmuir 2012, 28:17372-17380. 10.1021/la3024919.
189. Morris M.C., Vidal P., Chaloin L., Heitz F., Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 1997, 25:2730-2736.
190. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157:195-206. 10.1111/j.1476-5381.2009.00057.x.
191. Munyendo W.L., Lv H., Benza-Ingoula H., Baraza L.D., Zhou J. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules 2012, 2:187-202. 10.3390/biom2020187.
192. Mei L., Fu L., Shi K., Zhang Q., Liu Y., Tang J., Gao H., Zhang Z., He Q. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int. J. Pharm. 2014, 468:26-38. 10.1016/j.ijpharm.2014.04.008.
193. Mokhtarieh A.A., Kim S., Lee Y., Chung B.H., Lee M.K. Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs. Biochem. Biophys. Res. Commun. 2013, 432:359-364. 10.1016/j.bbrc.2013.01.096.
194. Liang J., Wu W.L., Xu X.D., Zhuo R.X., Zhang X.Z. pH responsive micelle self-assembled from a new amphiphilic peptide as anti-tumor drug carrier. Colloids Surf. B: Biointerfaces 2014, 114:398-403. 10.1016/j.colsurfb.2013.10.037.
195. Mokhtarieh A.A., Cheong S., Kim S., Chung B.H., Lee M.K. Asymmetric liposome particles with highly efficient encapsulation of siRNA and without non-specific cell penetration suitable for target-specific delivery. Biochim. Biophys. Acta 2012, 1818:1633-1641.
196. Prud'homme G.J., Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012, 3:921-939.
197. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science May 21 2010, 328(5981):1031-1035. 10.1126/science.1183057.
198. Agemy L., Friedmann-Morvinski D., Kotamraju V.R., Roth L., Sugahara K.N., Girard O.M., Mattrey R.F., Verma I.M., Ruoslahti E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17450-17455. (Erratum in: Proc. Natl. Acad. Sci. U. S. A. 111 (2014) 11906). 10.1073/pnas.1114518108.
199. Park J.H., von Maltzahn G., Zhang L., Derfus A.M., Simberg D., Harris T.J., Ruoslahti E., Bhatia S.N., Sailor M.J. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 2009, 5:694-700. 10.1002/smll.200801789.
200. Wu Y.L., Huang J., Xu J., Liu J., Feng Z., Wang Y., Lai Y., Wu Z.R. Addition of acysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo. Regul. Pept. 2010, 164:83-89. 10.1016/j.regpep.2010.05.003.
201. Chen R., Braun G.B., Luo X., Sugahara K.N., Teesalu T., Ruoslahti E. Application of a proapoptotic peptide to intratumorally spreading cancer therapy. Cancer Res. 2013, 73:1352-1361. 10.1158/0008-5472.CAN-12-1979.
202. Dai W., Fan Y., Zhang H., Wang X., Zhang Q., Wang X. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Drug Deliv. 2015, 22:10-20. 10.3109/10717544.2014.903580.
203. Yu K.F., Zhang W.Q., Luo L.M., Song P., Li D., Du R., Ren W., Huang D., Lu W.L., Zhang X., Zhang Q. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int. J. Nanomedicine 2013, 8:2473-2485. 10.2147/IJN.S46962.
204. Du R., Zhong T., Zhang W.Q., Song P., Song W.D., Zhao Y., Wang C., Tang Y.Q., Zhang X., Zhang Q. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. Int. J. Nanomedicine 2014, 9:3091-3105. (eCollection 2014). 10.2147/IJN.S65664.
205. Alberici L., Roth L., Sugahara K.N., Agemy L., Kotamraju V.R., Teesalu T., Bordignon C., Traversari C., Rizzardi G.P., Ruoslahti E. De novo design of a tumor-penetrating peptide. Cancer Res. 2013, 73:804-812. 10.1158/0008-5472.CAN-12-1668.
206. Corti A., Pastorino F., Curnis F., Arap W., Ponzoni M., Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med. Res. Rev. 2012, 32:1078-1091. 10.1002/med.20238.
207. Wang R.E., Niu Y., Wu H., Hu Y., Cai J. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging. Anti Cancer Agents Med. Chem. 2012, 12:76-86.
208. Ellerby H.M., Bredesen D.E., Fujimura S., John V. Hunter-killer peptide (HKP) for targeted therapy. J. Med. Chem. 2008, 51:5887-5892. (Erratum in: J. Med. Chem. 58 (2015) 2045). 10.1021/jm800495u.
209. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12:991-1003. 10.1038/nmat3776.
210. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 2012, 41:2971-3010. 10.1039/c2cs15344k.
211. Ge Z., Liu S. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chem. Soc. Rev. 2013, 42:7289-7325. 10.1039/c3cs60048c.
212. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol. (Camb.) 2013, 5:96-107. 10.1039/c2ib20135f.
213. Melancon M.P., Li C. Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents. Mol. Imaging 2011, 10:28-42.
214. Haas M., Moolenaar F., Elsinga A., Van der Wouden E.A., de Jong P.E., Meijer D.K., de Zeeuw D. Targeting of doxorubicin to the urinary bladder of the rat shows increased cytotoxicity in the bladder urine combined with an absence of renal toxicity. J. Drug Target. 2002, 10:81-89.
215. Guo L., Ding W., Zheng L.M. The C(RgdyK)-conjugated Fe3O4 nanoparticles with high drug load for dual-targeting integrin alpha(v)beta3-expressing cancer cells. J. Nanosci. Nanotechnol. 2014, 14:4858-4864.
216. Huang P., Song H., Wang W., Sun Y., Zhou J., Wang X., Liu J., Liu J., Kong D., Dong A. Integrin-targeted zwitterionic polymeric nanoparticles with acid-induced disassembly property for enhanced drug accumulation and release in tumor. Biomacromolecules 2014, 15:3128-3138. 10.1021/bm500764p.
217. Nazli C., Demirer G.S., Yar Y., Acar H.Y., Kizilel S. Targeted delivery of doxorubicin into tumor cells via MMP-sensitive PEG hydrogel-coated magnetic iron oxide nanoparticles (MIONPs). Colloids Surf. B: Biointerfaces 2014, 122:674-683. 10.1016/j.colsurfb.2014.07.049.
218. Gianella A., Mieszawska A.J., Hoeben F.J., Janssen H.M., Jarzyna P.A., Cormode D.P., Costa K.D., Rao S., Farokhzad O.C., Langer R., Fayad Z.A., Mulder W.J. Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem. Commun. (Camb.) 2013, 49:9392-9394. 10.1039/c3cc43618g.
219. Jiang T., Olson E.S., Nguyen Q.T., Roy M., Jennings P.A., Tsien R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17867-17872.
220. Crisp J.L., Savariar E.N., Glasgow H.L., Ellies L.G., Whitney M.A., Tsien R.Y. Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol. Cancer Ther. 2014, 13:1514-1525. 10.1158/1535-7163.MCT-13-1067.
221. Buckel L., Savariar E.N., Crisp J.L., Jones K.A., Hicks A.M., Scanderbeg D.J., Nguyen Q.T., Sicklick J.K., Lowy A.M., Tsien R.Y., Advani S.J. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015, 75:1376-1387. 10.1158/0008-5472.CAN-14-1931.
222. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30:631-637. 10.1038/nbt.2289.
223. Zhu L., Xie J., Swierczewska M., Zhang F., Lin X., Fang X., Niu G., Lee S., Chen X. Dual-functional, receptor-targeted fluorogenic probe for in vivo imaging of extracellular protease expressions. Bioconjug. Chem. 2011, 22:1001-1005. 10.1021/bc200005w.
224. Mebrahtu E., Zheleznyak A., Hur M.A., Laforest R., Lapi S.E. Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity. Nucl. Med. Biol. 2013, 40:190-196. 10.1016/j.nucmedbio.2012.10.003.
225. Quan C.Y., Chen J.X., Wang H.Y., Li C., Chang C., Zhang X.Z., Zhuo R.X. Core-shell nanosized assemblies mediated by the alpha-beta cyclodextrin dimer with a tumor-triggered targeting property. ACS Nano 2010, 4:4211-4219. 10.1021/nn100534q.
226. Sun C., Yang H., Yuan Y., Tian X., Wang L., Guo Y., Xu L., Lei J., Gao N., Anderson G.J., Liang X.J., Chen C., Zhao Y., Nie G. Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging. J. Am. Chem. Soc. 2011, 133:8617-8624. 10.1021/ja200746p.
227. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13:813-827. 10.1038/nrd4333.
228. Casagrande C., Arosio D., Kusmic C., Manzoni L., Menichetti L., L'Abbate A. Molecular targeting of imaging and drug delivery probes in atherosclerosis. Ann. Rep. Med. Chem. 2013, 48:105-118. 10.1016/B978-0-12-417150-3.00008-9.
229. Beer A.J., Kessler H., Wester H.J., Schwaiger M. PET imaging of integrin αVβ3 expression. Theranostics 2011, 1:48-57.
230. Xie F., Lof J., Matsunaga T., Zutshi R., Porter T.R. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 2009, 119:1378-1385. 10.1161/CIRCULATIONAHA.108.825067.
231. Kaul S. Sonothrombolysis: a universally applicable and better way to treat acute myocardial infarction and stroke? Who is going to fund the research?. Circulation 2009, 119:1358-1360. 10.1161/CIRCULATIONAHA.108.846113.
232. Bai Y.Y., Gao X., Wang Y.C., Peng X.G., Chang D., Zheng S., Li C., Ju S. Image-guided pro-angiogenic therapy in diabetic stroke mouse models using a multi-modal nanoprobe. Theranostics 2014, 4(2014):787-797. 10.7150/thno.9525.eCollection.
233. Peiris P.M., Toy R., Doolittle E., Pansky J., Abramowski A., Tam M., Vicente P., Tran E., Hayden E., Camann A., Mayer A., Erokwu B.O., Berman Z., Wilson D., Baskaran H., Flask C.A., Keri R.A., Karathanasis E. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano 2012, 6:8783-8795. 10.1021/nn303833p.
234. Peiris P.M., Toy R., Abramowski A., Vicente P., Tucci S., Bauer L., Mayer A., Tam M., Doolittle E., Pansky J., Tran E., Lin D., Schiemann W.P., Ghaghada K.B., Griswold M.A., Karathanasis E. Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J. Control. Release 2014, 173:51-58. 10.1016/j.jconrel.2013.10.031.
235. Lee S.Y., Ferrari M., Decuzzi P. Design of bio-mimetic particles with enhanced vascular interaction. J. Biomech. 2009, 42:1885-1890. 10.1016/j.jbiomech.2009.05.012.
236. Peiris P.M., Schmidt E., Calabrese M., Karathanasis E. Assembly of linear nano-chains from iron oxide nanospheres with asymmetric surface chemistry. PLoS One 2011, 6:e15927. 10.1371/journal.pone.0015927.
237. Kim M.S., Lee D.W., Park K., Park S.J., Choi E.J., Park E.S., Kim H.R. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes. Colloids Surf. B: Biointerfaces 2014, 116:17-25. 10.1016/j.colsurfb.2013.12.045.
238. Melancon M.P., Stafford R.J., Li C. Challenges to effective cancer nanotheranostics. J. Control. Release 2012, 164:177-182. 10.1016/j.jconrel.2012.07.045.
239. Lu W., Melancon M.P., Xiong C., Huang Q., Elliott A., Song S., Zhang R., Flores L.G., Gelovani J.G., Wang L.V., Ku G., Stafford R.J., Li C. Effects of photoacoustic imaging and photothermal ablation therapy mediated by targeted hollow gold nanospheres in an orthotopic mouse xenograft model of glioma. Cancer Res. 2011, 71:6116-6121. 10.1158/0008-5472.CAN-10-4557.
240. Melancon M.P., Zhou M., Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc. Chem. Res. 2011, 44:947-956. 10.1021/ar200022e.
241. 3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment. Theranostics 2015, 5:124-133. (eCollection 2015). 10.7150/thno.10014.
242. Sirsi S., Borden M. Microbubble compositions, properties and biomedical applications. Bubble Sci. Eng. Technol. 2009, 1:3-17.
243. Lindner J.R. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovasc. Imaging 2010, 3:204-211. 10.1016/j.jcmg.2009.09.021.
244. Plow E.F., Das M. Rising like the phoenix?. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2182-2183. 10.1161/ATVBAHA.114.304486.
245. Ellegala D.B., Leong-Poi H., Carpenter J.E., Klibanov A.L., Kaul S., Shaffrey M.E., Sklenar J., Lindner J.R. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003, 108:336-341.
246. Tartis M.S., McCallan J., Lum A.F., LaBell R., Stieger S.M., Matsunaga T.O., Ferrara K.W. Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med. Biol. 2006, 32:1771-1780.
247. Kiessling F., Fokong S., Koczera P., Lederle W., Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J. Nucl. Med. 2012, 53:345-348. 10.2967/jnumed.111.099754.
248. Li Y.H., Shi Q.S., Du J., Jin L.F., Du L.F., Liu P.F., Duan Y.R. Targeted delivery of biodegradable nanoparticles with ultrasound-targeted microbubble destruction-mediated hVEGF-siRNA transfection in human PC-3 cells in vitro. Int. J. Mol. Med. 2013, 31:163-171. 10.3892/ijmm.2012.1175.
249. Scaringi C., Minniti G., Caporello P., Enrici R.M. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Anticancer Res. 2012, 32:4213-4223.
250. Preusser M., Capper D., Ilhan-Mutlu A., Berghoff A.S., Birner P., Bartsch R., Marosi C., Zielinski C., Mehta M.P., Winkler F., Wick W., von Deimling A. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 2012, 123:205-222. 10.1007/s00401-011-0933-9.
251. Allhenn D., Boushehri M.A., Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int. J. Pharm. 2012, 436:299-310. 10.1016/j.ijpharm.2012.06.025.
252. Agrawal U., Chashoo G., Sharma P.R., Kumar A., Saxena A.K., Vyas S.P. Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting. Colloids Surf. B: Biointerfaces 2015, 126:414-425. 10.1016/j.colsurfb.2014.12.045.
253. Zhang P., Hu L., Yin Q., Feng L., Li Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol. Pharm. 2012, 9:1590-1598. 10.1021/mp200600t.
254. Miura Y., Takenaka T., Toh K., Wu S., Nishihara H., Kano M.R., Ino Y., Nomoto T., Matsumoto Y., Koyama H., Cabral H., Nishiyama N., Kataoka K. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 2013, 7:8583-8592. 10.1021/nn402662d.
255. Ding H., Inoue S., Ljubimov A.V., Patil R., Portilla-Arias J., Hu J., Konda B., Wawrowsky K.A., Fujita M., Karabalin N., Sasaki T., Black K.L., Holler E., Ljubimova J.Y. Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18143-18148. (Erratum in: Proc Natl Acad Sci U S A. 107 (2010) 19603). 10.1073/pnas.1003919107.
256. Fujita M., Lee B.S., Khazenzon N.M., Penichet M.L., Wawrowsky K.A., Patil R., Ding H., Holler E., Black K.L., Ljubimova J.Y. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J. Control. Release 2007, 122:356-363.
257. Peiris P.M., Abramowski A., Mcginnity J., Doolittle E., Toy R., Gopalakrishnan R., Shah S., Bauer L., Ghaghada K.B., Hoimes C., Brady-Kalnay S.M., Basilion J.P., Griswold M.A., Karathanasis E. Treatment of invasive brain tumors using a chain-like nanoparticle. Cancer Res. 2015, 75:1356-1365. 10.1158/0008-5472.CAN-14-1540.
258. Agemy L., Kotamraju V.R., Friedmann-Morvinski D., Sharma S., Sugahara K.N., Ruoslahti E. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. Mol. Ther. 2013, 21:2195-2204. 10.1038/mt.2013.191.
259. D'Abaco G.M., Kaye A.H. Integrins: molecular determinants of glioma invasion. J. Clin. Neurosci. 2007, 14:1041-1048.
260. Carbonell W.S., DeLay M., Jahangiri A., Park C.C., Aghi M.K. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013, 73:3145-3154. 10.1158/0008-5472.CAN-13-0011.
261. Wang T., Upponi J.R., Torchilin V.P. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Pharm. 2012, 427:3-20. 10.1016/j.ijpharm.2011.07.013.
262. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
263. Park J., Singha K., Son S., Kim J., Namgung R., Yun C.O., Kim W.J. A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther. 2012, 19:741-748. 10.1038/cgt.2012.64.
264. Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11:125-140. 10.1038/nrd3625.
265. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6:686-695. 10.1021/mp900093r.
266. Alam M.R., Ming X., Fisher M., Lackey J.G., Rajeev K.G., Manoharan M., Juliano R.L. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug. Chem. 2011, 22:1673-1681. 10.1021/bc200235q.
267. Liu X., Wang W., Samarsky D., Liu L., Xu Q., Zhang W., Zhu G., Wu P., Zuo X., Deng H., Zhang J., Wu Z., Chen X., Zhao L., Qiu Z., Zhang Z., Zeng Q., Yang W., Zhang B., Ji A. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res. 2014, 42:11805-11817. 10.1093/nar/gku831.
268. Dufès C., Uchegbu I.F., Schätzlein A.G. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 2005, 57:2177-2202.
269. Li G., Hu Z., Yin H., Zhang Y., Huang X., Wang S., Li W. A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int. J. Nanomedicine 2013, 8:1293-1306. 10.2147/IJN.S41555.
270. Pardo L.A., Contreras-Jurado C., Zientkowska M., Alves F., Stühmer W. Role of voltage-gated potassium channels in cancer. J. Membr. Biol. 2005, 205:115-124.
271. Liu X., Liu C., Chen C., Bentobji M., Cheillan F.A., Piana J.T., Qu F., Rocchi P., Peng L. Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system. Nanomedicine 2014, 10:1627-1636. 10.1016/j.nano.2014.05.008.
272. Ou M., Wang X.L., Xu R., Chang C.W., Bull D.A., Kim S.W. Novel biodegradable poly (disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug. Chem. 2008, 19:626-633. 10.1021/bc700397x.
273. Kim H.A., Nam K., Kim S.W. Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials 2014, 35:7543-7552. 10.1016/j.biomaterials.2014.05.021.
274. Leng Q., Scaria P., Lu P., Woodle M.C., Mixson A.J. Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther. 2008, 15:485-495. 10.1038/cgt.2008.29.
275. Chou S.T., Leng Q., Scaria P., Woodle M., Mixson A.J. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo. Cancer Gene Ther. 2011 Oct, 18(10):707-716. 10.1038/cgt.2011.40.
276. Chou S.T., Leng Q., Scaria P., Kahn J.D., Tricoli L.J., Woodle M., Mixson A.J. Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules 2013, 14:752-760. 10.1021/bm3018356.
277. Ragelle H., Vandermeulen G., Préat V. Chitosan-based siRNA delivery systems. J. Control. Release 2013 Nov 28, 172(1):207-218. 10.1016/j.jconrel.2013.08.005.
278. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 2008, 60:1307-1315. 10.1016/j.addr.2008.03.016.
279. Ding Y., Jiang Z., Saha K., Kim C.S., Kim S.T., Landis R.F., Rotello V.M. Gold nanoparticles for nucleic acid delivery. Mol. Ther. 2014, 22:1075-1083. 10.1038/mt.2014.30.
280. Conde J., Ambrosone A., Sanz V., Hernandez Y., Marchesano V., Tian F., Child H., Berry C.C., Ibarra M.R., Baptista P.V., Tortiglione C., de la Fuente J.M. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano 2012, 6:8316-8324.
281. Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.P., Ibarra M.R., Baptista P.V., Stoeger T., de la Fuente J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34:7744-7753. 10.1016/j.biomaterials.2013.06.041.
282. Lee J.H., Lee K., Moon S.H., Lee Y., Park T.G., Cheon J. All-in-one target-cell specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. Engl. 2009, 48:4174-4179. 10.1002/anie.200805998.
283. Qian J., Gao X. Triblock copolymer-encapsulated nanoparticles with outstanding colloidal stability for siRNA delivery. ACS Appl. Mater. Interfaces 2013, 5:2845-2852. 10.1021/am3021813.
284. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 2011, 8:250-259. 10.1021/mp100315q.
285. Zhang M.Z., Li C., Fang B.Y., Yao M.H., Ren Q.Q., Zhang L., Zhao Y.D. High transfection efficiency of quantum dot antisense oligonucleotide nanoparticles in cancer cells through dual-receptor synergistic targeting. Nanotechnology 2014, 25:255102. 10.1088/0957-4484/25/25/255102.